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Abstract. This paper presents REMPARK system, a novel approach to deal with 
Parkinson’s Disease (PD). REMPARK system comprises two closed loops of 
actuation onto PD. The first loop consists in a wearable system that, based on a 
belt-worn movement sensor, detects movement alterations that activate an auditory 
cueing system controlled by a smartphone in order to improve patient’s gait. The 
belt-worn sensor analyzes patient’s movement through real-time learning 
algorithms that were developed on the basis of a database previously collected 
from 93 PD patients. The second loop consists in disease management based on 
the data collected during long periods and that enables neurologists to tailor 
medication of their PD patients and follow the disease evolution. REMPARK 
system is going to be tested in 40 PD patients in Spain, Ireland, Italy and Israel. 
This paper describes the approach followed to obtain this system, its components, 
functionalities and trials in which the system will be validated. 
Keywords. Parkinson’s Disease, Wearable System, Disease Management 
Introduction 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disease after 
Alzheimer’s disease. PD is a progressive neurological condition, resulting from the 
degeneration of dopamine-producing neurons in the substantia nigra, which is located 
within the basal ganglia circuit, deep in the lower region of the brain. According to the 
World Health Organization, 5.2 million people suffer PD in the World [1]. Mortality is 
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two to five times higher among affected people than among age-matched controls [2]. 
Given that PD is mainly suffered by elderly people, and that this population group is 
growing PD is becoming a first magnitude public health problem [3], due to the 
associated reduced capacity for self-care and quality of life (QoL). 
Given the degeneration in the substantia nigra that PD provokes, patients suffer a 
lack of dopamine, which is one of the neurotransmitters involved in the control of 
movement. The symptoms of PD can be broadly classified into motor symptoms and 
non-motor symptoms. Motor symptoms (MS) include rigidity, tremor, bradykinesia 
(slow movement), postural alterations, tendency to fall, reduced gait speed, reduced 
step length, and episodes called freezing of gait (FoG) [7], which consists of a blockade 
of the motor activity, resulting in a sudden inability to start or continue walking, as if 
glued to the spot [4]. Non-motor symptoms (NMS) may include dementia, depression, 
anxiety, sleep initiation and sleep maintenance disturbances, urinary problems, sexual 
disturbances, olfactory dysfunction and fatigue [5][6]. 
Currently, there are two main approaches that are being researched in order to deal 
with PD symptoms: continuous [10][11] and discontinuous monitoring [8][9]. Both 
approaches aim to meet two goals: on the one hand, both monitoring types might have 
the purpose of providing richer information to neurologists and, on the other hand, they 
expect to lead to some specific actuations (listed later on) in order to increase the QoL 
of PD patients.  
Continuous monitoring devices consist in unobtrusive inertial sensors capable of 
continuously monitoring patients during daily life activities. These devices typically 
comprise inertial sensors (accelerometers, gyroscopes and magnetometers). Many 
examples exist in the literature, such as wrist sensors to monitor tremor [8], ankle 
sensors to monitor FoG and gait parameters [11] or waist sensors to monitor gait [10]. 
On the other hand, discontinuous monitoring devices require the patient to perform 
specific activities and, consequently, they are able to provide a snapshot of the current 
patient status at isolated times. For instance, Kinesia system is a device that requires 
the patient to perform specific motor exercises [12] similarly to the system presented 
by Patel et al. [8]. It should be noted that, although MS can be monitored either 
continuously or discontinuously, NMS are capable of being monitored only 
discontinuously since questionnaires and direct observation are the unique tools 
available to determine the current non-motor status of PD patients [13]. In this sense, it 
has been recently developed a specific questionnaire that quantifies their assessment in 
PD, which is called Non-Motor Symptoms Scale (NMSS), although other standard 
scales quantifies both NMS and MS such as Movement Disorder Society-Unified 
Parkinson's Disease Rating Scale (MDS-UPDRS) [13]. 
Monitoring of PD symptoms aims to improve patients’ QoL by actuating onto the 
disease. In this sense, different actuation paradigms can be found in the literature. First, 
it was recently tested the automatic regulation of the dosage administered by an 
infusion pump according to patient’s status, which was estimated by a waist sensor [14], 
similarly to current closed-loop approaches for diabetes. Second, since FoG episodes 
are mostly overcome by means of audio cues, an Auditory Cueing System (ACS), 
which consists of a small wireless earphone, was employed to provide these audio cues 
when FoG episodes were detected [11]. Finally, a closed-loop actuation consists in 
neurologists adjusting the medication regimen of patients according to the information 
provided by monitoring devices. 
This paper describes the REMPARK system, which is the first system that unites 
monitoring of both MS and NMS in PD as well as different actuation approaches. More 
concretely, REMPARK includes FoG and gait disturbances correction through audio 
cues and enables neurologists to adjust the medication regimen. Moreover, the 
REMPARK system has been also validated to control other actuators such as haptic 
cueing devices and apomorphine infusion pumps. This system is composed of two 
main components: a wearable system with FoG actuation capabilities and a cloud-
based service that enables neurologists, patients and caregivers to follow the disease 
evolution and communicate among them. This wearable system contains a belt-worn 
sensor that continuously monitors patients’ movement. This device analyzes in real-
time the signals provided by the sensor based on personalized machine learning 
algorithms that were developed from a database of labeled signals obtained from 93 PD 
patients [15]. REMPARK system has been recently developed and is going to be tested 
with 40 patients stemming from Spain, Italy, Ireland and Israel.  
The remainder of the paper is described as follows. First, the wearable system is 
described and, second, the cloud-based service is detailed. Then, the previously 
collected REMPARK database that enabled the development of movement disorder 
detection algorithms is presented. Next, the tests that will guide the validation of 
REMPARK system in 40 PD patients are presented and, finally, conclusions are 
presented. 
1. REMPARK wearable system 
REMPARK wearable system aims to monitor PD patients both continuously and 
discontinuously. It is composed of three devices: a movement sensor that continuously 
monitors MS and determines their presence in real-time, a headset capable of providing 
audio cues to PD patients in order to overcome FoG or improve their gait and, finally, a 
smartphone that discontinuously monitors both MS and NMS of patients, controls the 
audio cueing based on movement sensor information and sends the gathered 
information to the cloud-based service. Figure 1 depicts the structure of the wearable 
system. 
REMPARK wearable system not only provides a way of monitoring motor and 
non-motor fluctuations of PD patients, but also enables them to deal with FoG since the 
combination of its three elements helps to prevent and overcome FoG episodes. Thus, 
REMPARK wearable system can be also seen as a closed-loop system. 
The following subsections describe the complete REMPARK system according to 
each one of their components. 
  
Figure 1. REMPARK wearable system. 
 
1.1.  Movement sensor 
REMPARK movement sensor [16] is worn inside a hypoallergenic neoprene belt in 
order to locate it near the iliac crest. This sensor is capable of determining in real-time 
and at minute-basis the presence of bradykinesia, dyskinesia, FoG and falls. Moreover, 
it provides information on energy expenditure, cadence and if the patient has fallen at 
minute-level as well. This movement sensor has a Bluetooth connection by which 
shares the information with the smartphone. 
The waist device is composed of three triaxial inertial sensors (accelerometer, 
gyroscope and magnetometer), a microcontroller (dsPIC33F), a Bluetooth 
communication module and a memory unit. The microcontroller samples data at 200 
Hz. It also includes a Real-Time Clock/Calendar module that was calibrated against 
both Network Time Protocol (NTP) servers and frequency meters. A temperature 
correction by using an internal sensor is applied, obtaining a deviation lower than 40 
ms. in a 48-h period. Its dimensions are 77 x 37 x 21 mm and its weight, with the 
battery, is 78 g. 
This movement sensor determines the presence of bradykinesia, dyskinesia and 
FoG based on real-time machine learning approaches. These approaches employ, 
mainly, frequency features and 2
nd
 order statistics as the input for Support Vector 
Machines [10]. The algorithms were developed based on a database of signals that were 
gathered by the same movement sensor device and that were labeled by clinicians. 
Section 3 describes in detail this database, in which 93 PD patients participated. 
1.2. Auditory Cueing System  
The ACS employed in REMPARK system enables patients to overcome FoG and 
improve their gait. It consists of a wireless earphone that employs Bluetooth to 
communicate with the smartphone, which centralizes REMPARK’s wearable system.  
The auditory cueing is activated by the system as soon as FoG or bradykinesia are 
detected by the movement sensor. The provided cueing is composed of repetitive 
sounds that help patients regain their normal gait cadence [11]. Thus, once a patient has 
continued walking without bradykinesia or has stopped walking, the cueing is 
discontinued. The rhythm and volume of the cues provided by the ACS can be 
configured through the smartphone. 
The ACS can be any commercial Bluetooth headset with, at least, Bluetooth 
version 2.1 and A2DP profile. 
1.3. Smartphone 
The smartphone has different roles within REMPARK’s wearable system. First, it 
is the node in which the communications are centralized, since both movement sensor 
and ACS communicate with it. This way, it is also responsible of sending the collected 
data to the cloud-service so that they are available to clinicians. Second, it is in charge 
of controlling the ACS based on the current symptoms, as it has been previously 
described. Third, the smartphone offers patients a wide range of services to assist them 
in their activities of daily life through applications such as: medication manager, 
medication reminders, agenda or easy visualization of symptoms detected by the 
system. Finally, it performs a discontinuous monitoring of MS and NMS as it is 
explained below. The smartphone employed in REMPARK is a Samsung Galaxy 
Nexus. 
The discontinued monitoring performed by the smartphone provides a snapshot of 
patients’ status on a given instant. This snapshot is capable of providing information on 
both MS and NMS. On the one hand, the smartphone offers the patient specific games 
in which the motor state is analyzed. Two different tests are offered: 
 Tap Prompt: A mole appears on the screen in different positions and the user 
is asked to tap the appearing mole as soon as possible.  
 Touch a Button Repeatedly Prompt: The user is asked to press a button 
repeatedly for a predefined number of times in order to fill a container. 
On the other hand, the smartphone offers the possibility of filling in questionnaires 
or scales that enable clinicians to know the state of the patients. These scales can be 
answered by the same patient or by a caregiver. Finally, the smartphone also provides 
other tests that evaluate patients’ NMS, such as the backwards Corsi Prompt, in which 
a number of blocks are highlighted in sequence and then the user is asked to touch the 
squares that had previously been highlighted in a backwards sequence. 
2. Disease management  
REMPARK system comprises a second closed-loop that consists in the disease 
management, in which neurologists and caregivers are involved. Figure 2 depicts this 
second closed-loop system. 
Disease management gathers the information provided by the REMPARK 
wearable system. This information represents the long-term evolution of MS and NMS. 
This way, this information can be used by neurologists to provide suitable 
rehabilitation to their patients or tailor their medication regime. 
This second closed-loop of actuation is composed of different parts. Data send by 
REMPARK wearable system is collected in REMPARK server. With this server, a so-
called rule engine analyzes and enriches the information sent by the REMPARK 
wearable system. Then, this information is presented to patients, caregivers and 
clinicians through the so-called Disease Management Application (DMA). Finally, the 
DMA also enables neurologists to manage the disease by making appointments with 
patients or even change the medication regime. The following sections describe the 
different parts of the disease management loop. 
 
Figure 2. REMPARK disease management. 
2.1.  Server database and Rule Engine 
REMPARK’s central server collects all the information available from REMPARK 
wearable system. It is permanently updated so doctors are able to follow the evolution 
of the patients’ disease.  
Data collected in the server is processed through an intelligent data treatment at 
this second level based on a rule engine. This rule engine provides clinicians and 
patients a global overview of the patient situation, thus enabling them to translate the 
immediate information provided by the wearable system to the middle/long term scope.  
REMPARK central server consists of a standard database with different interface 
capabilities to communicate with the rest of the system elements. The rule engine 
consists in a service deployed in the same central server that enriches the information 
contained in it. 
2.2. Disease Management Application (DMA) - Monitoring and actuation 
DMA is a web application that not only presents the information collected in the 
central server in a suitable way to clinicians, caregivers and patients but also enables 
them to manage the disease by monitoring the evolution of MS and NMS, making 
appointments and by changing or informing about treatment plans. 
Consequently, the DMA has different interfaces depending on the role of a person 
within the disease management. Moreover, DMA interacts with the Electronic Health 
Record, so that information about the symptoms can be inserted in it by REMPARK 
system or, on the other hand, clinicians may improve treatment by knowing co-
morbidity related information. 
DMA is able to graphically present the information contained in the central server. 
For instance, it can graphically depict the presence of dyskinesia, bradykinesia or FoG 
along a day. Moreover, DMA enables clinicians to define deviation range from normal 
values and, when this deviation is given, the system pops up an alert on the clinicians 
interface and, in some cases, it presents protocols to overcome the situation. This way, 
thanks to data gathering and the rule engine, the DMA is also capable of providing 
decision support mechanism to the doctors, suggesting clinical actions. Finally, the 
DMA has the ability to ask patients to fill in a clinical assessment questionnaire by the 
smartphone. 
Finally, it should be noted that this solution is adequate for most PD population 
since it can be used at different settings of drug delivery through, for instance, pump or 
oral treatments. Thus, this second closed-loop of the REMPARK system is useful for 
different treatments and, consequently, at different stages of the disease progression. 
3. REMPARK database for movement disorders detection 
As it has been previously mentioned, REMPARK project has developed a database of 
signals and relevant clinical data from 93 PD patients in Israel, Italy, Ireland and Spain. 
This database led to the final REMPARK system that has been previously described 
and, moreover, enabled obtaining the movement disorder detection algorithms that 
monitor ON/OFF motor fluctuations and the detection of dyskinesia, bradykinesia and 
FoG symptoms. This section describes the data collected in this database. 
Data collection took place at patient’s home and lasted 4 to 8 hours, thus providing 
remarkable information on daily life environment of patients. Moreover, data collection 
was divided into two kinds of tests: 
 Short controlled tests during which patients were asked to perform certain 
activities so that specific motor symptoms, false positives, UPDRS scale 
values, gait speed and step/stride length were obtained. These tests were 
closely controlled so that an accurate gold-standard was obtained  
 Free activity monitoring of the patient so that natural symptoms and activities 
were recorded. This monitoring lasted for hours and the gold-standard used in 
these tests was not required to be as accurate as in the previous case.  
The two types of experiments took place in alternation and were performed in each 
motor state. Thus, when the patient was in the OFF phase, the specific controlled tests 
for the OFF symptoms were conducted and the remaining OFF state time was used for 
monitoring their free and natural activity. Similarly, when the patient entered the ON 
phase, some short tests for capturing ON symptoms were performed and the remaining 
time was devoted to monitoring the free natural activity. 
Data collected in this database comprise: 
 Relevant clinical data. It consists of UPDRS values obtained in each 
motor state, socio-demographic data and the presence of symptoms 
among the population. 
 Labeled inertial signals. These signals were acquired based on two inertial 
sensors: one in the wrist for assessing tremor and one in the waist near the 
Iliac Crest for detecting the rest of symptoms. The wrist device contains a 
triaxial accelerometer, a microcontroller and a communications unit. Its 
microcontroller acquired samples at 80 Hz and sent them to the waist 
sensor using a Bluetooth (BT) 2.1 link.  
Once the inertial signals were collected, typically a day after the experimentation, 
the signals corresponding to the short tests were labeled by clinicians according to the 
video recording taken during the tests. This way, since signals and videos were 
previously synchronized, signals were labeled according to the severity of each signal. 
Table 1 summarizes the amount of signals collected in the database according to 
different symptoms. 
Supervised learning algorithms were then employed to exploit them and the final 
algorithms were implemented in real-time within the movement sensor belonging to the 
REMPARK wearable system. 
 
Table 1. Summary of labeled inertial signals in REMPARK database. 
Symptom Amount of 
signals (h)  
Amount of signals 
in ON state (h) 
Amount of signals in 
intermediate state (h) 
Amount of signals 
in OFF state (h) 
Bradykinesia 45.2  2.9  5.6  36.8  
Dyskinesia 68.1  48.2 12.2  7.7  
Tremor 51.4  15.1  12.4  23.9  
FoG 4.8  0.9  0.7  3.2  
Total 360.4  170.3  73.5  116.6   
 
 
4. REMPARK system validation 
A validation of the described system will be performed by 40 PD patients from Italy, 
Israel, Spain and Ireland. A specific clinical study has been designed in order to study 
the performance and reliability of the REMPARK system under real conditions and to 
study the validity of the ON/OFF motor phase detection by the system. Moreover, the 
following secondary objectives have been set: 
1. To study the validity of questionnaires and tests administered via the 
smartphone in detecting ON/OFF states     
2. To investigate the validity of inventories administered via the smartphone to 
assess non-motor Parkinson's disease symptoms 
3. To study the efficacy of an auditory cueing system, activated by an algorithm, 
in improving FoG. 
4. To assess both usability and user's satisfaction referring to the REMPARK 
system application under real daily living conditions 
5. To study the validity of the fall detection algorithm of the REMPARK system. 
6. To verify the safety of the REMPARK system in individuals with PD. 
 
The reference population for this study is  formed by Parkinson's patients 
with moderate to severe disease and motor symptoms including ON/OFF phases, FOG 
or dyskinesia (Hoehn & Yahr scale value greater than 2 in ON phases and lower than 5 
in OFF phases).  
The validation will take place along 5 days. The first one will be employed to 
adjust the system to the patient, enabling detection algorithms to be personalized to 
each patient. The rest of the 4 days patients will be wearing and using REMPARK 
system under real conditions.  
For comparison purposes, patients will note down the exact time of every motor 
change they feel in a diary. In addition they will record their motor phase hourly in the 
ON-OFF diary.  This way, the accuracy of the motor state detection performed by 
REMPARK system will be measured. 
5. Conclusions 
This paper describes REMPARK system, which aims to increase QoL of PD patients 
and is composed of two closed-loop levels. The first one comprises a wearable system 
that enables disease management based on actuation against gait disturbances through 
audio cueing. The second closed-loop consists in a disease management that actuates 
on the mid-to-long term and that involves patients, caregivers and clinicians. 
REMPARK system enables the monitoring of MS and NMS at the same time. On 
the one hand, movement sensor and smartphone are in charge of establishing the motor 
state of PD patients, the former in a continuous way and the latter in specific instants 
given the interaction needed with the patient. On the other hand, the smartphone 
provides NMS monitoring through the questionnaires presented to patients. 
REMPARK system was developed by exploiting a database previously collected 
from 93 PD patients at their natural environment. This database provided 360 hours of 
inertial signals that were labeled by clinicians, which led to reliable movement disorder 
detection algorithms that are included in the movement sensor worn at waist. 
In the following months the validation of REMPARK system will start. It will be 
tested in Italy, Ireland, Spain and Israel by 40 PD patients during 4 days. 
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